Russ Conroy

Articles

mRNA-4157 Plus Pembrolizumab Bolsters RFS in Resected Melanoma

October 23rd 2023

The addition of mRNA-4157 to pembrolizumab led to clinically significant improvements in relapse-free survival and distant metastasis–free survival vs pembrolizumab alone in patients with high-risk resected melanoma.

Retrospective Analysis Shows Trastuzumab Deruxtecan Improves Intracranial Responses in HER2+ Breast Cancer

October 21st 2023

Fam-trastuzumab deruxtecan-nxki elicited higher rates of intracranial responses vs comparator therapies in patients with HER2-positive metastatic breast cancer with both stable and active brain metastases.

Durvalumab Plus Chemotherapy Elicits pCR Improvement in Resectable Gastric/GEJ Cancer

October 20th 2023

The addition of durvalumab to 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel produced statistically significant and clinically meaningful improvements in pathological complete response rates vs placebo plus FLOT in patients with resectable gastric cancer or gastroesophageal junction cancer.

Hypofractionated and Conventionally Fractionated Radiotherapy Generate Similar QOL, Safety in Breast Cancer

October 2nd 2023

Patients with breast cancer who received hypofractionated postmastectomy radiotherapy experienced similar toxicities vs those who received conventionally fractionated postmastectomy radiotherapy, according to a presentation shared at the 2023 American Society for Radiation Oncology Annual Meeting.

Daratumumab-Based Quadruplets Show Consistent Efficacy in Newly Diagnosed Myeloma, Despite Early Relapse in Select Subsets

September 29th 2023

Although quadruplet combination regimens featuring daratumumab demonstrated consistent efficacy in the treatment of patients with newly diagnosed multiple myeloma, certain prognostic factors were associated with early relapse, according to data from a retrospective analysis presented at the 2023 International Myeloma Society Annual Meeting.

Survival Outcomes May Be Impacted By Socio-Racial Factors in Primary Myelofibrosis

September 8th 2023

A retrospective analysis of the Surveillance, Epidemiology, and End Results database emphasized the potential impact of specific socio-racial factors, such as race, sex, and age, on survival outcomes in patients with primary myelofibrosis.

Adjuvant Pembrolizumab Provides Survival Benefit Across ccRCC Risk Groups and Disease Stages

July 14th 2023

Adjuvant pembrolizumab prolonged disease-free survival and distant metastasis-free survival compared with placebo across The University of California Los Angeles Integrated Staging System–categorized subgroups of patients with clear cell renal cell carcinoma.

Frontline Lenvatinib Plus Pembrolizumab Produces Superior Responses Vs Sunitinib in Advanced RCC

July 14th 2023

Lenvatinib plus pembrolizumab demonstrated improved overall response rates compared with sunitinib monotherapy in treatment-naïve patients with advanced renal cell carcinoma regardless of risk status or PD-L1 expression.

Imaging Mass Cytometry May Identify Therapeutic Targets in ccRCC

July 13th 2023

The tumor-immune evasion cell networks in clear cell renal cell carcinoma may be captured and classified using imaging mass cytometry, an orthogonal approach with the potential for increased cost-efffectiveness and accuracy compared with single-cell RNA sequencing.

Cilta-Cel Demonstrates Long-Term PFS, Safety in R/R Multiple Myeloma

June 11th 2023

Administration of a single infusion of ciltacabtagene autoleucel prolonged progression-free survival, generated sustained responses, and continued to demonstrate a manageable safety profile in patients with relapsed/refractory multiple myeloma who were heavily pretreated, according to final results from the phase 1b/2 CARTITUDE-1 study.

Teclistamab Plus Talquetamab Demonstrates Encouraging ORR in Relapsed/Refractory Multiple Myeloma

June 10th 2023

The combination of the BCMA- and GPRC5D-targeted bispecific antibodies, teclistamab and talquetamab, respectively, demonstrated encouraging overall response rates and was well tolerated in patients with relapsed or refractory multiple myeloma.

Eftilagimod Alpha Plus Pembrolizumab Generates Responses, Safety in Metastatic HNSCC

June 6th 2023

The addition of the soluble LAG-3 protein eftilagimod alpha to pembrolizumab produced responses and was well tolerated in patients with metastatic head and neck squamous cell carcinoma.

Addition of Up-front Durvalumab, Maintenance Olaparib to Standard Therapy Improves PFS in Advanced Ovarian Cancer

June 3rd 2023

The addition of durvalumab to standard upfront therapy with chemotherapy and bevacizumab followed by maintenance bevacizumab, durvalumab, and olaparib led to a statistically significant improvement in progression-free survival compared with chemotherapy and bevacizumab alone in patients with newly diagnosed, advanced ovarian cancer without a BRCA1/2 mutation.

Nivolumab Plus Cabozantinib Shows Sustained Survival Advantage in Advanced RCC

February 19th 2023

The combination of nivolumab and cabozantinib produced prolonged progression-free survival and higher response rates compared with sunitinib alone as frontline therapy in patients with advanced renal cell carcinoma, regardless of International Metastatic RCC Database Consortium risk status.

Neoadjuvant Tremelimumab/Durvalumab Elicits Responses in Gastric/GEJ Adenocarcinoma

January 19th 2023

Neoadjuvant treatment with the combination of tremelimumab and durvalumab produced responses and was well tolerated in patients with mismatch repair–deficient and microsatellite instability–high, Epstein-Barr virus–negative gastric or gastroesophageal junction adenocarcinoma.

Teclistamab Triplet Shows Encouraging Responses and Safety in Relapsed/Refractory Multiple Myeloma

December 10th 2022

Administration of teclistamab in combination with daratumumab and lenalidomide demonstrated promising overall response rates and tolerability in patients with relapsed/refractory multiple myeloma who had prior lenalidomide exposure, according to initial data from the phase 1b MajesTEC-2 trial.